Protagonist Therapeutics, Inc. Financials

Market Capitalization $2.25 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	13.80
Forward PE	-26.43
Price to Sales TTM	$6.96
Price to Book MRQ	$4.23
Enterprise to Revenue	5.54
Enterprise to EBITDA	11.96

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	52.76%
Operating Margin	-886.69%
Return on Assets TTM	19.96%
Return on Equity TTM	40.97%

Income Statement

Revenue TTM	$323,795,008
Revenue per Share TTM	$5.30
Quarterly Revenue Growth	12.19%
Gross Profit TTM	$323,795,008
EBITDA	$150,068,000
Net Income to Common TTM	$170,848,992
Diluted EPS TTM	$2.74
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	$468,720,992
Total Cash per Share MRQ	$7.87
Total Debt MRQ	$
Total Debt to Equity MRQ	2.05
Current Ratio MRQ	10.70
Book Value per Share MRQ	$8.94

Cash Flow

Operating Cash Flow TTM	$230,290,000
Levered Free Cash Flow TTM	$144,935,008

PTGX Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	59,598,000
Float Shares	44,378,472
Avg 10 Volume	568,120
Avg 30 Volume	None
Shares Short	3,798,682
Short Ratio	5.76
Short % of Shares	6.46%
% Held by Insiders	1.39%
% Held by Institutions	106.31%

Stock Price Summary

Beta	2.16
Fifty Two Week Low	$24.22
Fifty Two Week High	$48.89
Fifty Two Week Change	29.37%
Day 50 MA	$40.52
Day 200 MA	$38.04

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date